$AUPH Conclusion: AUR200 is a BCMA-IgG4 Fc fusion protein currently in preclinical development. AUR200 demonstrates best in class binding affinity to both BAFF and APRIL due to the engineered modifications to the BCMA binding pocket. In a mouse model of SLE, AUR200 dosed therapeutically reduced several markers of disease activity and improved overall survival. AUR200 was well-tolerated, in both mouse and cynomolgus monkeys, with no adverse effects. These data highlight the potential utility for AUR200 in the treatment of autoimmune diseases. acrabstracts.org/abstract/a...
AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases - ACR Meeting Abstractsvia: ACR Meeting Abstracts